Final Study Results Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress

Dateline City:
KENILWORTH, N.J., & WOODCLIFF LAKE, N.J.

KENILWORTH, N.J., & WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced final results from the full endometrial cancer cohort of KEYNOTE-146/Study 111 evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, an orally available kinase inhibitor discovered by Eisai. The primary endpoint was objective response rate (ORR) at week 24 as assessed by investigators per immune-related Response Evaluation Criteria in Solid Tumors (irRECIST).

Language:
English

Contact:

Merck Media Relations
Pamela Eisele: (267) 305-3558
Kristen Drake: (908) 334-4688

Merck Investor Relations
Courtney Ronaldo: (908) 740-6132

Eisai Inc. Media Relations
Michele Randazzo: (201) 746-2979

Ticker Slug:
Ticker:
MRK

Exchange:
NYSE

@Merck

read more

Read Original Article: Final Study Results Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress »